Showing results (11-20 of 31) with videos related to
Sort By:
Pageof 4
Antimicrobial Agents and Chemotherapy|May 16, 2012
The cyclophilin inhibitor SCY-635 disrupts hepatitis C virus NS5A-cyclophilin A complexesSam Hopkins, Michael Bobardt, Udayan Chatterji, et al.Antimicrobial Agents and Chemotherapy|March 21, 2012
Sublimable C5A delivery provides sustained and prolonged anti-HIV microbicidal activitiesRichard Maskiewicz, Michael Bobardt, Udayan Chatterji, et al.Scientific Reports|August 5, 2020
Highly synergistic drug combination prevents vaginal HIV infection in humanized miceMarc M Baum, Christina M Ramirez, John A Moss, et al.Antimicrobial Agents and Chemotherapy|November 16, 2011
PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virusAna Maria Chamoun, Karuppiah Chockalingam, Michael Bobardt, et al.Plos One|March 1, 2024
Mice lacking cyclophilin B, but not cyclophilin A, are protected from the development of NASH in a diet and chemical-induced modelWinston T Stauffer, Asha Z Goodman, Michael Bobardt, et al.Gastroenterology|October 12, 2014
Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen productionSandra Phillips, Shilpa Chokshi, Udayan Chatterji, et al.Proceedings of the National Academy of Sciences of the United States of America|November 28, 2007
Syndecan-3 is a dendritic cell-specific attachment receptor for HIV-1Lot de Witte, Michael Bobardt, Udayan Chatterji, et al.Plos One|February 5, 2019
The inhibitor apoptosis protein antagonist Debio 1143 Is an attractive HIV-1 latency reversal candidateMichael Bobardt, Joseph Kuo, Udayan Chatterji, et al.Journal of Hepatology|August 21, 2012
HCV NS5A and IRF9 compete for CypA bindingMichael Bobardt, Sam Hopkins, James Baugh, et al.Antimicrobial Agents and Chemotherapy|November 13, 2013
Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicideAna M Chamoun-Emanuelli, Michael Bobardt, Bernard Moncla, et al.Pageof 4